Transcranial Magnetic Brain Stimulation for Cannabis Use
This study is testing a device called transcranial magnetic brain stimulation (iTBS) to see if it can help heavy cannabis users reduce their cannabis use. Researchers believe that by stimulating a specific area of the brain (the left dorsolateral prefrontal cortex), they might be able to reduce how much attention people pay to cannabis-related cues, which could help them cut back on use. The study is looking for 50 participants between 18 and 65 years old who are current cannabis users. To see if the treatment works, researchers will track how often and how much cannabis participants use over several weeks. The current status of this study is unclear.
- Study design
- This interventional study plans to enroll 50 participants. It uses both active and sham (inactive) iTBS, meaning some participants will receive the real treatment and others a placebo-like treatment.
- What's involved
- Participants will undergo a two-week pre-treatment phase, a two-week treatment phase, and a four-week post-treatment phase, totaling eight weeks of observation.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for four weeks after the treatment phase to assess their cannabis use.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Tonisha Kearney-Ramos, PhD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Frequency of cannabis useTwo-week Pre-treatment/Baseline phase (Days 1-14), Two-week Treatment phase (Days 15-28), Four-week Post-treatment phase (Days 29-56)
On each study day, participants will receive EMA text surveys on their cellphones. For each participant, cannabis use frequency will be measured as the number of days per week they report cannabis use. During the two-week pre-treatment period, we will calculate the baseline frequency as the average number of use days per week across those two weeks. Cannabis use frequency will then be assessed during each of the two treatment weeks (Week 0-1) and during the four-week follow-up period (Weeks 2-5), and the follow-up period will subsequently be compared relative to baseline. This is corroborated by TLFB.
- Quantity of cannabis useTwo-week Pre-treatment/Baseline phase (Days 1-14), Two-week Treatment phase (Days 15-28), Four-week Post-treatment phase (Days 29-56)
On each study day, participants will receive EMA text surveys on their cellphones. For each participant, cannabis use quantity will be measured as the average number of grams used per use-day during each week in which they report cannabis use. During the two-week pre-treatment/baseline period (Days 1-14), we will calculate the baseline quantity as the average daily grams used per use-day across those two weeks. Cannabis use quantity will then be assessed during the treatment phase (Days 15-28) and during the 4-week follow-up period (Days 29-56), and the follow-up period will subsequently be compared relative to baseline. This will be corroborated by TLFB.